.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Fish and Richardson
Cerilliant
Baxter
McKesson
Moodys
Chinese Patent Office
UBS
QuintilesIMS
Farmers Insurance

Generated: July 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Phenyl carbamate
Abstract:The (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenylncarbamate in free base or acid addition salt form is useful as pharmaceutical, particularly for systemic transdermal administration.
Inventor(s): Enz; Albert (Basel, CH)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:08/466,502
Patent Claims: 1. The (S)-[N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenyl-carbamate] enantiomer of formula I substantially free of its (R) isomer ##STR3## in free base or acid addition form.

2. The compound of claim 1 which is the hydrogen tartrate salt of (S)-N-ethyl-3-[(1-dimethylamino)ethyl]-N-methyl-phenylcarbamate.

3. A pharmaceutical composition which comprises a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.

4. A method of treating senile dementia, which comprises administering a therapeutically effective amount of a compound of claim 1 in free base or pharmacologically acceptable acid addition salt form to a subject in need of such treatment.

5. A method of treating Alzheimer's disease, which comprises administering a therapeutically effective amount of a compound of claim 1 in free base or pharmacologically acceptable acid addition salt form to a subject in need of such treatment.

6. A method of treating Huntington's chorea, tardive dyskinesias, hyperkinesia, mania, acute confusion disorders, Down's syndrome or Friedrich's ataxia, which comprises administering a therapeutically effective amount of a compound of claim 1 in free base or pharmacologically acceptable acid addition salt form to a subject in need of such treatment.

7. A method of systemically administering a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, which comprises administering the active agent transdermally through the skin.

8. A systemic transdermal pharmaceutical composition according to claim 3 comprising a therapeutically effective amount of (S)-N-ethyl-3-[(1-dimethyl-amino)ethyl]-N-methyl-phenyl-carbamate in free base or pharmaceutically acceptable acid addition salt form, and a pharmaceutically acceptable carrier therefor suitable for systemic transdermal administration.

9. A systemic transdermal pharmaceutical composition according to claim 3 comprising a therapeutically effective amount of the hydrogen tartrate salt of (S)-N-ethyl-3-[(1-dimethyl-amino)ethyl]-N-methyl-phenyl-carbamate, and a pharmaceutically acceptable carrier therefor suitable for systemic transdermal administration.

10. A systemic transdermal pharmaceutical composition according to claim 8 in which the (S)-N-ethyl-3-[(1-dimethyl-amino)ethyl]-N-methyl-phenyl-carbamate is in free base form.

11. A systemic transdermal pharmaceutical composition according to claim 8 in which the pharmaceutically acceptable carrier is a transdermal patch.

12. A method according to claim 7 in which the compound is in free base form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
US Department of Justice
Moodys
Healthtrust
Johnson and Johnson
Novartis
Merck
Deloitte
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot